Viewing Page 5 of 6 | Showing Results 41 - 50 of 58

In Case You Missed It

August 19, 2010

 Here’s an informative article from the Issaquah Reporter about Swedish’s plans for the new hospital:

Desmoteplase may hold the key for stroke patients

August 12, 2010

Acute stroke is the third leading cause of mortality and the major cause of long-term disability in the developed world. Ischemic strokes account for about 85 percent of all acute strokes and are caused by clots that block blood vessels in the brain, stopping the flow of blood to crucial brain areas.

The main approach to treating acute ischemic stroke is thrombolysis, which degrades the clot causing the stroke and provides significant clinical improvements. The only thrombolytic intervention for acute ischemic stroke that is currently approved by the U.S. Food and Drug Administration (FDA) is alteplase. However, alteplase must be administered within three hours after symptom onset to avoid the risk of inducing a hemorrhage in the brain. (More recent evidence supports delivering alteplase up to 4.5 hours.) Because of this time limitation, it is estimated that alteplase is currently administered to less than five percent of acute stroke patient...

Unfundable: Clinical trials for rare diseases and orphan drugs

August 11, 2010

The study of acetazolamide for idiopathic intracranial hypertension described on page 9 of the Spring issue of BrainWaves raises an important question about a neglected aspect of clinical trials: How do investigators obtain funding to study the efficacy of a drug that has no commercial potential?

Only 300 of the approximately 7,000 known human diseases are of interest to the biopharmaceutical industry from the standpoint of prevalence or commercial potential, according to the Office of Rare Diseases Research (ORDR) at the National Institutes of Health (NIH). The Orphan Drug Act of 1983 sought to use patent protection and tax incentives to promote development of drugs for diseases with a small market. In this context, the word “orphan” refers to a condition or drug that has not been “adopted” by the pharmaceutical...

Issaquah Tops Off

August 11, 2010

 The last steel beam for Swedish’s new Issaquah hospital and outpatient center was lifted into place Aug. 6 in a special topping-off ceremony. The beam was signed by construction workers and hospital officials before being lifted into place atop the structure. The topping-off completes a construction milestone en route to the facility’s phase-one opening in July 2011 in the Issaquah Highlands. Once completed, it will be the first new hospital built in King County in 25 years and will include an ambulatory care center, five-story medical office building and acute-care community hospital.

3rd Annual Brain Cancer Walk Raises Over $426,000

August 05, 2010

Over 2,000 people arrived at the Seattle Center’s Mural Amphitheatre on Saturday, June 26th to show their support in raising awareness and finding a cure for brain cancer. There has been over $426,000 raised and the numbers continue to climb.

The walk was hosted by Accelerate Brain Cancer Cure and proceeds from the Seattle Brain Cancer Walk will benefit organizations focusing on brain cancer research and patient care in the Pacific Northwest, including the 0 comment(s)|Read More

Cruising along!

July 10, 2010

 This afternoon, Sellen Construction placed the last piece of structural steel on the medical office building portion of the new Swedish campus in the Issaquah Highlands.


View of the medical office building

Top Ten Things to Know About Swedish Issaquah

June 29, 2010

What if you could build a brand-new hospital from scratch? How would you build it to be the most patient-friendly, forward-thinking facility of its kind? Swedish has that opportunity on this new Issaquah Highlands campus. Here are the top 10 reasons why this facility will be different:

Ketogenic Diet for Seizures in Childen

June 25, 2010
The ketogenic diet is a well-recognized, effective, non-pharmacologic treatment for intractable pediatric epilepsy. The diet, which is high fat and low carbohy­drate, alters the metabolic biochemistry in the brain to utilize fat and ketones, rather than carbohydrates and glucose, as the primary energy source. Meals are care­fully calculated and prepared, accounting for all grams of fat, protein and carbohydrates. A great deal of moti­vation is required from the patient and parents in order to adhere to this strictly cal­culated diet.
Using ketones as the primary fuel source has proven to dramatically reduce the occurrence of seizures. Approximately two-thirds of patients on the ketogenic diet experience 50 percent or greater reduction in seizure frequency and 10-15 percent of patients experience complete seizure free...

A Glimpse Inside Swedish Issaquah

June 09, 2010

 Here are a couple renderings of the inside of the medical center. Swedish/Issaquah will not only be one of the most energy-efficient health-care facilities in the country, but a place with a comfortable atmosphere.

The medical center is designed to be a warm, comforting environment emphasizing natural light, spectacular views and healing gardens.

Main entry/lobby area

SNI Sees Major Expansion

June 06, 2010

Swedish Neuroscience Institute (SNI) is moving forward with plans to increase the availability of tertiary neurological care for patients in the Pacific Northwest. "Eight new providers will join the SNI staff in August," noted Marc Mayberg, MD, co-director of SNI, "adding specialty care in neuro-otology, functional radiosurgery, and neuropsychiatry, and expanding our existing programs in multiple sclerosis, stroke, neuromuscular disease, pediatric neurology, and general neurology." An upcoming issue of the SNI newsletter, BrainWaves, will provide more detail about these new providers and programs. Stay tuned for updates.